Clinical Trials Browser

Phase 1/2 × enfortumab vedotin × 30 days × Clear all

NCT07232602 2026-04-13

MK-3475-04D

Phase 1/2 Recruiting

Urinary Bladder Neoplasms

NCT07421700 2026-04-07

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Phase 1/2 Recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07287995 2026-04-01

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Phase 1/2 Recruiting

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT03288545 2026-03-24

EV-103

Phase 1/2 Terminated

348 enrolled 2 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms